Image Credits : Pixabay | Visual for illustration purposes
1 minute read

Japanese company Daiichi-Sankyo is investing one billion euros in Germany

The Japanese pharmaceutical company Daiichi-Sankyo is investing one billion euros to develop and produce its new generation of cancer drugs in Pfaffenhofen, Upper Bavaria. The company announced this on Friday.

This involves so-called antibody-drug conjugates (ADCs). To put it simply, these are chemotherapies that work directly in the cancer cell. The products are revolutionary for patients and the market potential is huge.

According to estimates by market research firm Markets and Markets, global sales of ADCs will double from almost $10 billion last year to nearly $20 billion in 2028.

Daiichi-Sankyo, together with the British pharmaceutical company Astra-Zeneca, sells the currently fastest-growing ADC Enhertu, which is used in the treatment of inoperable breast cancer, but now also for the treatment of lung cancer and stomach cancer.

Legal Disclaimer:
Handelsblatt
GLOBAL FLOW CONTROL provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above. "

Latest News

  • Oil and Gas
    1 minute read

    Ivory Coast Plans to Triple Oil…

    19 Jun. 2024 | Global Flow Control
  • LNG and Industrial Gases
    1 minute read

    Technip Energies awarded new contract at…

    19 Jun. 2024 | Global Flow Control
  • Hydrogen and Carbon Capture
    3 minutes read

    McDermott Selected by Abraxas Power for…

    19 Jun. 2024 | Global Flow Control
  • Mining and Metals
    2 minutes read

    Occidental Petroleum and Berkshire Hathaway Join…

    18 Jun. 2024 | Global Flow Control